Skip to content

Edwards Lifesciences Corporation: 10-Q filed 2014-08-04

What Edwards Lifesciences Corporation reported in its quarterly report filed 2014-08-04 (fiscal Q2 2014): 30 published measures, 84 facts as tagged in accession 0001047469-14-006621.

This filing

Form
10-Q (quarterly report)
Filed
2014-08-04
Fiscal period
fiscal Q2 2014
Accession
0001047469-14-006621 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Edwards Lifesciences Corporation filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-303,326,600,000USD
At 2013-12-312,709,900,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-301,914,900,000USD
At 2013-12-311,544,400,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-06-30498,600,000USD
At 2013-12-31420,400,000USD
At 2013-06-30372,700,000USD
At 2012-12-31310,900,000USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-06-3030,300,000USD181
2013-01-01 to 2013-06-3066,300,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-06-302,638,100,000USD
At 2013-12-312,030,800,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-04-01 to 2014-06-30105,600,000shares91
2014-01-01 to 2014-06-30106,100,000shares181
2013-04-01 to 2013-06-30112,600,000shares91
2013-01-01 to 2013-06-30113,300,000shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-04-01 to 2014-06-30107,400,000shares91
2014-01-01 to 2014-06-30107,900,000shares181
2013-04-01 to 2013-06-30114,700,000shares91
2013-01-01 to 2013-06-30115,600,000shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-04-01 to 2014-06-305.18USD/shares91
2014-01-01 to 2014-06-305.72USD/shares181
2013-04-01 to 2013-06-300.83USD/shares91
2013-01-01 to 2013-06-302.09USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-04-01 to 2014-06-305.09USD/shares91
2014-01-01 to 2014-06-305.63USD/shares181
2013-04-01 to 2013-06-300.81USD/shares91
2013-01-01 to 2013-06-302.05USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-04-01 to 2014-06-30266,200,000USD91
2014-01-01 to 2014-06-30283,200,000USD181
2013-04-01 to 2013-06-3027,200,000USD91
2013-01-01 to 2013-06-3073,900,000USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-06-30422,500,000USD
At 2013-12-31421,600,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-06-3023,900,000USD181
2013-01-01 to 2013-06-3024,000,000USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-302,278,100,000USD
At 2013-12-311,725,800,000USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2014-06-30384,300,000USD
At 2013-12-31385,400,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2014-06-3029,500,000USD
At 2013-12-3128,900,000USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2014-01-01 to 2014-06-30300,600,000USD181
2013-01-01 to 2013-06-30246,600,000USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2014-06-30317,100,000USD
At 2013-12-31308,900,000USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2014-04-01 to 2014-06-30423,900,000USD91
2014-01-01 to 2014-06-30800,400,000USD181
2013-04-01 to 2013-06-30393,600,000USD91
2013-01-01 to 2013-06-30769,300,000USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2014-04-01 to 2014-06-30215,500,000USD91
2014-01-01 to 2014-06-30412,700,000USD181
2013-04-01 to 2013-06-30186,600,000USD91
2013-01-01 to 2013-06-30369,000,000USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-04-01 to 2014-06-3089,100,000USD91
2014-01-01 to 2014-06-30174,900,000USD181
2013-04-01 to 2013-06-3080,500,000USD91
2013-01-01 to 2013-06-30160,300,000USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-30106,000,000shares
At 2013-12-31109,300,000shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-06-30-41,100,000USD
At 2013-12-31-27,600,000USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2014-06-3029,500,000USD
At 2013-12-3133,500,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-06-3035,700,000USD
At 2013-12-3135,400,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-06-30273,200,000USD
At 2013-12-31226,800,000USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2014-04-01 to 2014-06-30538,300,000USD91
2014-01-01 to 2014-06-30593,800,000USD181
2013-04-01 to 2013-06-3097,300,000USD91
2013-01-01 to 2013-06-30227,100,000USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-04-01 to 2014-06-30547,000,000USD91
2014-01-01 to 2014-06-30607,300,000USD181
2013-04-01 to 2013-06-3093,300,000USD91
2013-01-01 to 2013-06-30237,200,000USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2014-01-01 to 2014-06-3032,300,000USD181
2013-01-01 to 2013-06-3028,800,000USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2014-04-01 to 2014-06-302,000,000USD91
2014-01-01 to 2014-06-304,100,000USD181
2013-04-01 to 2013-06-302,500,000USD91
2013-01-01 to 2013-06-305,000,000USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-06-3011,500,000USD181
2013-01-01 to 2013-06-3031,700,000USD181

Inspect the source

Entity
Edwards Lifesciences Corporation / CIK 0001099800
Captured
2026-09-20T05:22:59.752Z
SEC response SHA-256
5e8f751fbec9a0a1ff653c4d2070ea46d6cde3f7ccf35f9c1d7367a126bc76c1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001099800.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))